Cincor Pharma Forum: Community User: Solix

✌️

🤔

👍

..Übernahme durch AstraZeneca

Analysts at Jefferies Financial Group raised their Q3 2022 earnings estimates for CinCor Pharma in a note issued to investors on Wednesday, September 7th. Jefferies Financial Group analyst D. Ding now forecasts that the company will earn ($0.54) per share for the quarter, up from their prior forecast of ($0.60). The consensus estimate for CinCor Pharma's current full-year earnings is ($2.39) per share. Jefferies Financial Group also issued estimates for CinCor Pharma's Q4 2022 earnings at ($0.50) EPS, FY2022 earnings at ($2.09) EPS, Q1 2023 earnings at ($0.52) EPS, Q2 2023 earnings at ($0.60) EPS, Q3 2023 earnings at ($0.68) EPS, Q4 2023 earnings at ($0.75) EPS and FY2023 earnings at ($2.55) EPS.

22% 👌

☕️

👀

CinCor Pharma, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase. Das Unternehmen konzentriert sich auf die Entwicklung seines führenden klinischen Kandidaten, CIN-107, zur Behandlung von Bluthochdruck und anderen kardio-renalen Erkrankungen.